Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies
- 1 February 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in BioDrugs
- Vol. 24 (1), 23-39
- https://doi.org/10.2165/11530560-000000000-00000
Abstract
Monoclonal antibodies (mAbs) have complex pharmacology; pharmacokinetics and pharmacodynamics depend on mAb structure and target antigen. mAbs targeting soluble antigens often exhibit linear phar-macokinetic behavior, whereas mAbs targeting cell surface antigens frequently exhibit nonlinear behavior due to receptor-mediated clearance. Where nonlinear kinetics exist, clearance can change due to receptor loss following repeated dosing and/or disease severity. mAb pharmacodynamics are often indirect, with delayed clinically relevant outcomes. This behavior provides challenges during clinical development; studies must be carefully planned to account for complexities specific to each agent. Selection of a starting dose for human studies can be difficult. Species differences in pharmacology need to be considered. Various metrics are available for scaling from animals to humans. Optimal dose selection should ensure uniform mAb exposure across all individuals. Traditional approaches such as flat dosing and variable dosing based upon body surface area or weight should be supported by pharmacokinetic and pharmacodynamic behavior, including target antigen and concurrent disease states. The use of loading doses or dose adjustments to improve clinical response is also a consideration. The evaluation of drug interactions requires innovative designs. Due to the pharmacokinetic properties of mAbs, interacting drugs may need to be administered for protracted periods. Consequently, population pharmacokinetic and pharmacodynamic model-based approaches are often implemented to evaluate mAb drug interactions.Keywords
This publication has 66 references indexed in Scilit:
- Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque PsoriasisThe Journal of Clinical Pharmacology, 2009
- Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and NeckThe Journal of Clinical Pharmacology, 2008
- Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment responseBritish Journal of Clinical Pharmacology, 2007
- Pharmacokinetics and Pharmacodynamics of Argatroban in Combination With a Platelet Glycoprotein IIB/IIIA Receptor Antagonist in Patients Undergoing Percutaneous Coronary InterventionThe Journal of Clinical Pharmacology, 2004
- The clinical pharmacology of therapeutic monoclonal antibodiesDrug Development Research, 2004
- Selection of the First‐Time Dose in Humans: Comparison of Different Approaches Based on Interspecies Scaling of ClearanceThe Journal of Clinical Pharmacology, 2003
- Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First RelapseThe Journal of Clinical Pharmacology, 2001
- Expression of GnTIII in a recombinant anti‐CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCγRIIIBiotechnology & Bioengineering, 2001
- Antibody Structure and Molecular ImmunologyScience, 1973
- THE CATABOLISM OF HOMOLOGOUS AND HETEROLOGOUS 7S GAMMA GLOBULIN FRAGMENTSThe Journal of Experimental Medicine, 1965